New research has revealed a confronting life-expectancy gap for people with intellectual disability in NSW, highlighting ...

Deportation practices in the USA continue to undermine the communication and disability rights of asylum seekers with disabilities, especially deaf individuals, causing serious health consequences and ...

Increasing evidence suggests that the severe gum disease, periodontitis, may contribute to central nervous system disorders through chronic inflammation. However, its role in multiple sclerosis, a ...

Among multiple sclerosis (MS) patients, those with a high relative abundance of Fusobacterium nucleatum together with other periodontal bacteria were more likely to have moderate to severe disability ...

PERSEUS phase 3 study in primary progressive multiple sclerosis did not meet its primary endpoint in delaying time to onset of 6-month composite confirmed disability progression compared to placebo ...

Multiple sclerosis (MS) is a chronic neurodegenerative disease that frequently causes neurogenic lower urinary tract dysfunction (NLUTD). More than 75% of patients experience urinary symptoms that ...

Cladribine was associated with similar relapse rates and MRI activity as sphingosine-1-phosphate receptor modulators (S1PRMs) in treatment-naive patients with relapsing-remitting multiple sclerosis ...

Some treatments for multiple sclerosis (MS) help ease day-to-day symptoms, while others can help control an attack (relapse). Other medicines are designed to limit further damage to the nervous system ...

Many women with multiple sclerosis (MS) notice a worsening of symptoms or progression just as menopause begins. While getting older is linked with disease progression in both men and women, hormones ...

- The first (FENhance 2) of two pivotal RMS studies met its primary endpoint, showing investigational fenebrutinib significantly reduced relapses compared to teriflunomide - - In a pivotal PPMS study ...

Genentech’s Fenebrutinib Shows Unprecedented Positive Phase III Results as the Potential First and Only BTK Inhibitor in Both Relapsing and Primary Progressive Multiple Sclerosis - The first (FENhance ...